Company news
Lenz Therapeutics, Inc. (NASDAQ:LENZ) news
Every Lenz Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
August 4, 2026
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presby...
July 6, 2026
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Z...
June 24, 2026
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
June 7, 2026
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 11, 2026
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Inve...
May 4, 2026
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency ...
April 20, 2026
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
March 24, 2026
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
March 17, 2026
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of ...
March 11, 2026
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of...
March 10, 2026
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
January 14, 2026
LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign
January 14, 2026
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
January 7, 2026
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
January 5, 2026
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
December 1, 2025
LENZ Therapeutics to Present at Upcoming Investor Conferences
November 25, 2025
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 5, 2025
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
October 29, 2025
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
October 27, 2025
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
September 30, 2025
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
September 30, 2025
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
August 25, 2025
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
July 31, 2025
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
July 30, 2025
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
July 28, 2025
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
July 7, 2025
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea...
May 9, 2025
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
May 7, 2025
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
May 6, 2025
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
April 30, 2025
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
March 19, 2025
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
March 11, 2025
LENZ Therapeutics to Host Commercial Day on April 15, 2025
March 3, 2025
LENZ Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2025
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
November 6, 2024
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
October 30, 2024
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
October 27, 2024
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
October 21, 2024
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
September 30, 2024
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
August 14, 2024
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presb...
August 12, 2024
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
August 7, 2024
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
July 15, 2024
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
June 10, 2024
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 8, 2024
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
May 1, 2024
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
April 3, 2024
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
April 2, 2024